Balchem(US:BCPC) Globenewswire·2025-10-21 11:00Core Insights - Balchem Corporation reported strong financial results for the third quarter of 2025, with net sales reaching $267.6 million, a year-over-year increase of 11.5% [6][8] - The company achieved net earnings of $40.3 million, reflecting a 19.1% increase compared to the same quarter last year [6][8] - Adjusted EBITDA for the quarter was $71.4 million, up 11.0% from the prior year [6][8] Financial Performance - Net sales for the third quarter were $267.6 million, compared to $239.9 million in the prior year quarter, marking an increase of $27.6 million [5][6] - Gross margin increased to $95.5 million, up 11.8% from $85.4 million in the prior year [11] - Operating expenses rose to $40.9 million, an increase of $3.5 million from the previous year [11] Segment Performance - The Human Nutrition and Health segment generated record sales of $174.1 million, a 14.3% increase from the prior year [8][18] - The Animal Nutrition and Health segment reported sales of $56.4 million, a 6.6% increase year-over-year [9][18] - The Specialty Products segment achieved sales of $35.7 million, reflecting a 7.5% increase compared to the previous year [10][18] Cash Flow and Debt Management - Cash flows from operations were $65.6 million, with free cash flow amounting to $50.7 million [6][13] - The company made net repayments on its revolving debt of $36.0 million, reducing net debt to $88.9 million [6][13] Strategic Initiatives - Balchem received approvals to construct a new microencapsulation manufacturing facility in Orange County, NY, which will significantly increase production capacity [6] - The company reported positive outcomes from its sponsored research, including a significant study on choline intake [6]